copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Mallinckrodt - Wikipedia Mallinckrodt Mallinckrodt Pharmaceuticals plc is an Irish-American manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents [2] In 2017, it had 5,500 employees and sales of $3 2 billion, of which $2 9 billion was from the U S healthcare system [3]
Mallinckrodt to take over Endo in deal valued at $6. 7 billion Ireland’s Mallinckrodt will buy U S drugmaker Endo in a cash-and-stock deal valued at $6 7 billion The companies said Thursday that Endo shareholders will receive a total of $80 million in cash and own nearly 50% of the combined company
Mallinckrodt and Endo to Combine to Create a Global, Scaled . . . About Mallinckrodt Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies
Mallinckrodt Completes Spin-Off of Par Health, Introduces Keenova . . . DUBLIN , Nov 10, 2025 PRNewswire -- Mallinckrodt plc ("Mallinckrodt") today announced the completion of the planned spin-off of its Par Health generic pharmaceuticals and sterile injectables businesses Moving ahead, Mallinckrodt will be known as Keenova Therapeutics ("Keenova" or the "Company") and will focus on developing, manufacturing, and commercializing branded therapeutics that help
Our Products | Mallinckrodt Pharmaceuticals Mallinckrodt has a diverse portfolio of branded products available across a broad range of indications and a broad line of speciality generics Visit our website to learn about our product offerings
Drugmaker Mallinckrodt files for second bankruptcy in US Mallinckrodt, which makes both branded and generic drugs, had first filed for bankruptcy in 2020 to address its high debt load, litigation over its marketing of highly addictive generic opioids